ATE384699T1 - 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten - Google Patents

2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten

Info

Publication number
ATE384699T1
ATE384699T1 AT03747411T AT03747411T ATE384699T1 AT E384699 T1 ATE384699 T1 AT E384699T1 AT 03747411 T AT03747411 T AT 03747411T AT 03747411 T AT03747411 T AT 03747411T AT E384699 T1 ATE384699 T1 AT E384699T1
Authority
AT
Austria
Prior art keywords
naphthhyl
quinolinyl
derivatives
related diseases
vla
Prior art date
Application number
AT03747411T
Other languages
English (en)
Inventor
Marie-Agnes Lassoie
Laurent Knerr
Thierry Demaude
Laveleye-Defais Francoise De
Thierry Kogej
Sylvain Routier
Gerald Guillaumet
Luc Quere
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE384699T1 publication Critical patent/ATE384699T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
AT03747411T 2002-04-30 2003-04-15 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten ATE384699T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02009746 2002-04-30

Publications (1)

Publication Number Publication Date
ATE384699T1 true ATE384699T1 (de) 2008-02-15

Family

ID=29286106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03747411T ATE384699T1 (de) 2002-04-30 2003-04-15 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten

Country Status (24)

Country Link
US (2) US7638630B2 (de)
EP (2) EP1870402A1 (de)
JP (1) JP2005535583A (de)
KR (1) KR100841165B1 (de)
CN (2) CN101200450A (de)
AR (1) AR039341A1 (de)
AT (1) ATE384699T1 (de)
AU (1) AU2003232472B2 (de)
BR (1) BR0309719A (de)
CA (1) CA2484954C (de)
CO (1) CO5450243A1 (de)
CU (1) CU23415B7 (de)
DE (1) DE60318839T2 (de)
ES (1) ES2298543T3 (de)
IL (1) IL164516A0 (de)
MX (1) MXPA04010673A (de)
MY (1) MY135218A (de)
NO (1) NO20045234L (de)
NZ (1) NZ536180A (de)
PL (1) PL373763A1 (de)
RU (1) RU2315041C2 (de)
TW (2) TWI267508B (de)
WO (1) WO2003093237A1 (de)
ZA (1) ZA200408447B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE384699T1 (de) * 2002-04-30 2008-02-15 Ucb Pharma Sa 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
ES2548419T3 (es) * 2003-02-20 2015-10-16 Ajinomoto Co., Inc. Procedimiento para producir un derivado de fenilalanina que tiene esqueleto de quinazolindiona e intermedio para el mismo
US7145005B2 (en) 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
MY140739A (en) * 2005-06-09 2010-01-15 Ucb Pharma Sa 2, 6-quinolinyl derivatives, processes for preparing them and their uses
CN101605762A (zh) 2006-11-14 2009-12-16 参天制药株式会社 具有取代苯基氨基低级烷基和导入酯结构的苯基作为取代基的新型1，2-二氢喹啉衍生物
WO2008125215A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008125210A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases
WO2008138592A1 (en) * 2007-05-14 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138615A1 (en) * 2007-05-16 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
EP2085407A1 (de) 2008-02-04 2009-08-05 Sahltech I Göteborg AB Behandlung von idiopathischer thrombozytopenischer Purpura
GEP20146061B (en) * 2008-05-12 2014-03-25 Santen Pharmaceutical Co Ltd Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl- 1,2-dihydroquinoline derivative having substituted oxy group
EP2467159A1 (de) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 als biomarker zur prognose und target zur behandlung der duchenne-muskeldystrophie
US20150368213A1 (en) * 2014-06-20 2015-12-24 The University of Montana, Missoula, MT Novel Inhibitors of System Xc-
MX385777B (es) * 2014-12-24 2025-03-04 Lg Chemical Ltd Derivado de biarilo como agonista de gpr120.
EP4467565A3 (de) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf-alpha-antikörperformulierungen
AU2019373244B2 (en) 2018-10-30 2022-05-26 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
JP7635962B2 (ja) * 2021-01-12 2025-02-26 国立大学法人山口大学 フルオロアルキル置換ビニルフルオロアルカンスルホニルアミドの製造方法
EP4284947A1 (de) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur beurteilung des risikos der entwicklung progressiver multifokaler leukoenzephalopathie bei patienten mit vla-4-antagonisten
CN116410136B (zh) * 2023-03-03 2025-07-11 五邑大学 一种喹啉衍生物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0655996T3 (da) * 1992-08-19 2001-12-27 Pfizer Substituerede benzylamino-nitrogenholdige, ikke-aromatiske, heterocykliske forbindelser
US5550139A (en) * 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors
WO1996018606A1 (en) 1994-12-14 1996-06-20 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivatives
JP2920741B2 (ja) * 1994-12-14 1999-07-19 参天製薬株式会社 新規１，３−ジアルキルウレア誘導体
JPH0987291A (ja) * 1995-09-26 1997-03-31 Wakamoto Pharmaceut Co Ltd 新規なアラニン誘導体
EP0977989A1 (de) 1997-02-04 2000-02-09 Trega Biosciences, Inc. 4-substituierte chinolinderivate und kombinatorische 4-substituierte-chinolin-bibliotheken
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
DK1005445T3 (da) 1997-08-22 2004-10-04 Hoffmann La Roche N-alkanoylphenylaninderivater
NZ509781A (en) 1998-08-26 2003-05-30 Aventis Pharma Ltd Quinoline or indolyl derivativees useful for modulating the inhibition of cell adhesion
WO2000066572A1 (en) 1999-04-28 2000-11-09 Dr. Reddy's Research Foundation Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
US6280442B1 (en) * 1999-09-01 2001-08-28 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US6399599B1 (en) * 1999-10-13 2002-06-04 Novartis Ag Substituted 2-oxo-1,4-diazacycloalkanes
ATE384699T1 (de) * 2002-04-30 2008-02-15 Ucb Pharma Sa 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
MY140739A (en) 2005-06-09 2010-01-15 Ucb Pharma Sa 2, 6-quinolinyl derivatives, processes for preparing them and their uses

Also Published As

Publication number Publication date
MY135218A (en) 2008-02-29
CA2484954A1 (en) 2003-11-13
AU2003232472A1 (en) 2003-11-17
ZA200408447B (en) 2006-07-26
US20080064720A1 (en) 2008-03-13
EP1501801B1 (de) 2008-01-23
US7638630B2 (en) 2009-12-29
ES2298543T3 (es) 2008-05-16
US20100105681A1 (en) 2010-04-29
NO20045234L (no) 2005-01-18
TWI268278B (en) 2006-12-11
DE60318839D1 (de) 2008-03-13
IL164516A0 (en) 2005-12-18
MXPA04010673A (es) 2005-09-30
KR20040106425A (ko) 2004-12-17
TW200616960A (en) 2006-06-01
CN1649842A (zh) 2005-08-03
NZ536180A (en) 2005-04-29
WO2003093237A1 (en) 2003-11-13
AU2003232472B2 (en) 2008-09-18
TWI267508B (en) 2006-12-01
CU23415B7 (es) 2009-09-08
KR100841165B1 (ko) 2008-06-24
JP2005535583A (ja) 2005-11-24
PL373763A1 (en) 2005-09-19
BR0309719A (pt) 2005-02-09
TW200404061A (en) 2004-03-16
CA2484954C (en) 2010-02-09
AR039341A1 (es) 2005-02-16
DE60318839T2 (de) 2009-01-22
EP1870402A1 (de) 2007-12-26
EP1501801A1 (de) 2005-02-02
CN101200450A (zh) 2008-06-18
CO5450243A1 (es) 2004-10-29
RU2004135304A (ru) 2005-07-10
RU2315041C2 (ru) 2008-01-20

Similar Documents

Publication Publication Date Title
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE425965T1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE455106T1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
ATE420866T1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE451921T1 (de) Phenylindole zur behandlung von hiv
ATE534635T1 (de) N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE362923T1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
DE60308045D1 (de) Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1501801

Country of ref document: EP

REN Ceased due to non-payment of the annual fee